ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Impact of tumor on the cell cycle and differentiation of hematopoietic stem cells
About authors
1 Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia
2 Novosibirsk State Medical University, Novosibirsk, Russia
3 Immunopathology Clinic, Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia
Correspondence should be addressed: Alina A. Aktanova
Yadrintsevskaya, 14, Novosibirsk, 630099, Russia; ur.liam@la_avonatka
About paper
Funding: the study was supported by the Russian Science Foundation, project No. 23–25-10099.
Author contribution: Aktanova AA — study design, experimental procedure, data analysis and interpretation, manuscript writing and editing; Bykova MV — literature review, data interpretation, manuscript editing; Skachkov IP — sample preparation, handling illustrations; Denisova VV — providing the biomaterials for the study, advising; Pashkina EA — planning, developing and editing the study design, data analysis, manuscript editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of the Research Institute of Fundamental and Clinical Immunology (protocol No. 145 dated 19 April 2024). All the conditionally healthy donors submitted the informed consent to participation in the study.
Received: 2024-12-02
Accepted: 2024-12-16
Published online: 2024-12-27
|
Fig. 1. Assessment of viability and proliferative activity of the hematopoietic stem cells co-cultured (c-c) with the conditioned media from the tumor cells lines 1301, К562, and SK-mel (10%, 50%, and 100% dilution) for 72 h (А), 120 h (B) , and 168 h (C) (WST). Friedman test, significant differences p < 0.05, data are provided as median and interquartile range; # — significant differences from the control STEM; ! — significant differences from the control DMSO; * — significant differences, p < 0.05; ** — significant differences, p < 0.005
Fig. 2. Assessment of viability and proliferative activity of the tumor cell lines 1301, К562, and SK-mel37 (А) and hematopoietic stem cells (B) co-cultured in transwells (t) for 72 h. Friedman test, significant differences p < 0.05, data are provided as median and interquartile range; # — significant differences from the control DMSO; ! — trend compared to the SK-mel 37 HSC 1:10, p = 0.05; * — significant differences, p < 0.05
Fig. 3. Relative number of the common progenitors of hematopoietic stem cells co-cultured with the tumor cell lines 1301, К562, and SK-mel37 in the co-culture (c-c) and transwells (t) for 72 h. Friedman test, significant differences p < 0.05, data are provided as median and interquartile range; * — significant differences compared to t К562, p < 0.05
Fig. 4. Relative number of hematopoietic stem cell progenitors co-cultured with the tumor cell lines 1301, К562, and SK-mel37 in the co-culture (c-c) and transwells (t) for 72 h. Friedman test, significant differences p < 0.05, data are provided as median and interquartile range; * — significant differences from the control RPMI, t К562; ** — significant differences compared to all test groups, p < 0.005; ! — trend compared to the t К562, p = 0.06; # — trend compared to the control before incubation and RPMI, p = 0.05
Table. Relative number of hematopoietic stem cells in various phases of the cell cycle during co-cultivation with the tumor cell lines 1301, К562, and SK-mel37 in the
co-culture (c-c) and transwells (t) for 72 h.
Note: Friedman test, significant differences p < 0.05; * — significant differences compared to the c-c К562 1/1, c-c 1301 1/1; * * — significant differences compared to the c-c 1301 1/10, c-c SK-mel37 1/10, RPMI 1/10; * * * — significant differences compared to the t SK-mel37 1/1, c-c SK-mel37 1/10, t К562 1/10, t 1301 1/10, RPMI 1/10; ! — significant differences from the control RPMI in equivalent concentrations; !! — significant differences compared to the t 1301 1/1; # — trend, p = 0.05 compared to c-c 1301 1/1, t 1301 1/10; $ — significant differences compared to the t SK-mel37 1/1, c-c SK-mel37 1/10, t К562 1/10, t 1301 1/10, RPMI 1/10
